I was reading the article by Dr West, How long should we continue immune checkpoint inhibitor therapy in patients who respond?
This was written in 2016 so I wondered if there is any more info now?
My partner has been on opdivo treatment for 3b nsclc for a little over a year. It’s worked well with all lung tumours stable. He has had lymph node increases, but the oncologist didn’t seem worried.
But lately he has been very tired, he gets increased shortness of breath (he has emphysema as well but the treatment definitely makes this worse). He also doesn’t want to eat much, although is maintaining his weight so this is not really a problem.
He’s just generally lacklustre and flat. He’s only skipped 2 treatments. One maybe 6 or 7 months ago, and then he skipped one 3 weeks ago. Then did another a week ago. He definitely picks up if he skips a treatment.
It’s difficult to know what to do. I tend to think/feel he should start skipping them now and again. If he says he’s discontinuing treatment he can’t get back on, but he can skip them without triggering any bureaucratic rules. But he has the attitude he’ll do the treatment if he’s up for it.
He’s not impressed with my women’s intuition as a good standard of evidence for skipping a few treatments, so I’ve been looking to see if there’s anything more concrete. I’ve asked our oncologist, but he always says, the drug is new, so nobody knows. Human bodies are all different, nobody knows.
Are there any studies/info about frequency of treatments, frequency of treatments etc? I have read somewhere that the treatment keeps working even after stopping it, which makes me think he could get away with skipping some.